Retinal Vascular Disease Take-Home Panel

Related

• 

  48-Week End of Study Results From BEHOLD Phase 2 Study of UBX1325 in Patients With DME

  Arshad M. Khanani, MD, MA, FASRS

  Annual Meeting Talks

  2023

• 

  FIDO Study: 10-Year Outcomes of Eyes Receiving Continuous, Fixed-Interval Dosing of Anti-VEGF Agents for Neovascular Age-Related Macular Degeneration

  Ivan J. Suner, MD, MBA

  Annual Meeting Talks

  2019

• 

  First Results From a Phase 1B Multiple-Dose Study of KSI-301: A Novel Anti-VEGF Antibody Biopolymer Conjugate (ABC) With Extended Durability

  Pravin U. Dugel, MD

  Annual Meeting Talks

  2019